Oncology View: Issue 2

Molecular Profiling Made Simple

We’re excited to announce that the PanTracer portfolio is expanding again with the launch of PanTracer Pro, a streamlined solution delivering comprehensive genomic and tailored biomarker insights for optimal therapy selection in a single order.

In the evolving landscape of precision oncology, accessing tumor-specific biomarker information is critical for patient care. PanTracer Pro combines comprehensive genomic profiling of 500+ cancer-related genes with cancer type-directed ancillary testing*, including IHC and HRD scoring, to provide personalized insights for therapy selection.

We are proud to introduce PanTracer Pro to you, the latest addition to the PanTracer family, delivering on our promise of powerful, simple solutions for therapy selection.

*The diagnosis information you provide will determine tumor type-directed IHC and ancillary testing. See neogenomics.com/pantracer-portfolio#pro for associated add-ons by cancer diagnosis

With highly sensitive MRD technology that detects circulating tumor DNA in blood before imaging, RaDaR ST reveals evidence of recurrence. Wherever the signal starts, find it with RaDaR ST.

RaDaR ST analyzes each patient’s unique tumor profile to develop a personalized panel – then uses that panel to detect the presence or absence of circulating tumor DNA in the patient’s bloodstream.

When cancer leaves only molecular traces, RaDaR ST brings them into view.

Learn more

Are you using NGS testing for patients with myeloid disorders? 

Guidelines recommend next-generation sequencing (NGS) at diagnosis for precise risk stratification, emphasizing its superior diagnostic value and cost-effectiveness compared to single-gene testing.¹

Comprehensive NGS testing at diagnosis changes everything for myeloid patients:

• Detects 74% more actionable biomarkers
• Boosts targeted therapy use by 12%
• Cuts non-targeted chemo by 40%²

Neo Comprehensive^® – Myeloid Disorders, a CGP assay, uses DNA and RNA NGS to detect relevant aberrations for diagnostic evaluation, prognosis, risk stratification, and therapy guidance for a wide range of myeloid disorders.

Recent advancements in targeted therapy for NSCLC patients: HGFR (MET) is a new actionable biomarker with an FDA-approved targeted therapy for NSCLC patients.

The National Comprehensive Cancer Network (NCCN) guidelines have recently been updated to use the term "HGFR" (Hepatocyte Growth Factor Receptor) for the c-MET protein biomarker.

In the era of precision medicine, the number of FDA-approved targeted therapy options has accelerated; this is particularly true for lung cancer.³ HGFR (MET) is a new actionable biomarker with an FDA-approved targeted therapy for NSCLC patients that could improve patient outcomes.

NeoGenomics is proud to offer c-MET CDx for NSCLC to support precision oncology in non-small cell lung cancer (NSCLC). This advanced immunohistochemistry (IHC) assay enables precise detection of HGFR (MET) protein expression, empowering oncologists to identify patients with NSCLC who may benefit from a new targeted therapy.

1. Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia. Haematologica. 2019 May;104(5):868-871. doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28. PMID: 30923100; PMCID: PMC6518900. 
2. Rosenquist R, Bernard E, Erkers T, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413-436. 
3. https://www.lungcancerresearchfoundation.org/research/why-research/treatment-advances/